Difference between revisions of "Immune thrombocytopenia"
Jump to navigation
Jump to search
Warner-admin (talk | contribs) m (Text replacement - "#Rituximab_.28Rituxan.29" to "#Rituximab_monotherapy") |
Warner-admin (talk | contribs) m (Text replacement - "color:#eeee00"|Seems not superior" to "color:#ffffbf"|Seems not superior") |
||
| Line 48: | Line 48: | ||
|style="background-color:#00CD00"|Phase III | |style="background-color:#00CD00"|Phase III | ||
|[[Autoimmune_thrombocytopenic_purpura_(ITP)#Prednisone_.28Sterapred.29|Prednisone]] | |[[Autoimmune_thrombocytopenic_purpura_(ITP)#Prednisone_.28Sterapred.29|Prednisone]] | ||
| − | |style="background-color:# | + | |style="background-color:#ffffbf"|Seems not superior |
|- | |- | ||
|} | |} | ||
| Line 198: | Line 198: | ||
|style="background-color:#00CD00"|Phase III | |style="background-color:#00CD00"|Phase III | ||
|[[#Dexamethasone.2C_high-dose|Dexamethasone]] | |[[#Dexamethasone.2C_high-dose|Dexamethasone]] | ||
| − | |style="background-color:# | + | |style="background-color:#ffffbf"|Seems not superior |
|- | |- | ||
|} | |} | ||
| Line 525: | Line 525: | ||
|style="background-color:#00CD00"|Phase III | |style="background-color:#00CD00"|Phase III | ||
|[[Autoimmune_thrombocytopenic_purpura_(ITP)#Rituximab_monotherapy|Rituximab]] | |[[Autoimmune_thrombocytopenic_purpura_(ITP)#Rituximab_monotherapy|Rituximab]] | ||
| − | |style="background-color:# | + | |style="background-color:#ffffbf"|Seems not superior |
|- | |- | ||
|[http://www.thelancet.com/journals/lancet/article/PIIS0140-6736(15)61107-2/fulltext Grainger et al. 2015 (PETIT2)] | |[http://www.thelancet.com/journals/lancet/article/PIIS0140-6736(15)61107-2/fulltext Grainger et al. 2015 (PETIT2)] | ||
| Line 571: | Line 571: | ||
|style="background-color:#00CD00"|Phase III | |style="background-color:#00CD00"|Phase III | ||
|[[Autoimmune_thrombocytopenic_purpura_(ITP)#Placebo|Placebo]] | |[[Autoimmune_thrombocytopenic_purpura_(ITP)#Placebo|Placebo]] | ||
| − | |style="background-color:# | + | |style="background-color:#ffffbf"|Seems not superior |
|- | |- | ||
|} | |} | ||
Revision as of 03:34, 22 August 2017
Use of this site is subject to you reading and agreeing with the terms set forth in the disclaimer.
Is there a regimen missing from this list? Would you like to share a different dosage/schedule or an additional reference for a regimen? Have you noticed an error? Do you have an idea that will help the site grow to better meet your needs and the needs of many others? You are invited to contribute to the site.
20 regimens on this page
30 variants on this page
|
Initial therapy
Dexamethasone, high-dose
| back to top |
Regimen #1
| Study | Evidence | Comparator | Efficacy |
| Wei et al. 2015 | Phase III | Prednisone | Superior CR rate |
- Dexamethasone (Decadron) 40 mg/day PO on days 1 to 4
One course
If platelets remained below 30 x 109/L or bleeding by day 10, course is repeated once.
Regimen #2
| Study | Evidence | Comparator | Efficacy |
| Matschke et al. 2013 | Phase III | Prednisone | Seems not superior |
Pre-dexamethasone
- Prednisone (Sterapred) 1 mg/kg/day for 7 days
Pulsed dexamethasone
- Dexamethasone (Decadron) 0.6 mg/kg/day for days 1 to 4
3-week cycle for 6 cycles
Regimen #3
| Study | Evidence |
| Cheng et al. 2003 | Phase II |
- Dexamethasone (Decadron) 40 mg PO once per day on days 1 to 4
4-day course
Patients who had an initial response, but whose platelets dropped below 30 x 109/L within 6 months received:
- Dexamethasone (Decadron) 40 mg PO once per day on days 1 to 4
- Prednisone (Sterapred) 15 mg PO once per day starting on day 5, "with gradual tapering"
Regimen #4, monthly dexamethasone
| Study | Evidence |
| Mazzucconi et al. 2007 | Phase II |
- Dexamethasone (Decadron) 40 mg PO once per day on days 1 to 4
- Patients who had platelet counts of less than or equal to 20 x 109/L between cycles received Prednisone (Sterapred) 0.25 mg/kg PO once per day "between courses"
28-day cycle for 6 cycles
Regimen #5, bi-weekly dexamethasone
| Study | Evidence |
| Mazzucconi et al. 2007 | Phase II |
- Dexamethasone (Decadron) as follows:
- Adults: 40 mg PO/IV once per day on days 1 to 4
- Patients less than 15 years old: 20 mg/m2 (maximum dose: 40 mg per day) PO/IV once per day on days 1 to 4
- Patients who had platelet counts of less than or equal to 30 x 109/L between cycles and/or who had bleeding related to thrombocytopenia received 0.035 mg/kg PO once per day "between courses"
14-day cycle for 4 cycles
References
- Cheng Y, Wong RS, Soo YO, Chui CH, Lau FY, Chan NP, Wong WS, Cheng G. Initial treatment of immune thrombocytopenic purpura with high-dose dexamethasone. N Engl J Med. 2003 Aug 28;349(9):831-6. link to original article contains verified protocol PubMed content property of HemOnc.org
- Mazzucconi MG, Fazi P, Bernasconi S, De Rossi G, Leone G, Gugliotta L, Vianelli N, Avvisati G, Rodeghiero F, Amendola A, Baronci C, Carbone C, Quattrin S, Fioritoni G, D'Alfonso G, Mandelli F; Gruppo Italiano Malattie EMatologiche dell'Adulto (GIMEMA) Thrombocytopenia Working Party. Therapy with high-dose dexamethasone (HD-DXM) in previously untreated patients affected by idiopathic thrombocytopenic purpura: a GIMEMA experience. Blood. 2007 Feb 15;109(4):1401-7. Epub 2006 Oct 31. link to original article contains verified protocol PubMed
- Abstract: Johannes Matschke, Hannes Müller-Beißenhirtz, Ilona Vester, Bernd Hertenstein, Lewin Eisele, Hildegard Lax, Claudia Ose, Ulrich Dührsen. A Randomized Trial Of Daily Prednisone Versus Pulsed Dexamethasone In Treatment Naïve Patients With Idiopathic Thrombocytopenic Purpura. Blood Nov 2013,122(21)325. link to abstract
- Wei Y, Ji XB, Wang YW, Wang JX, Yang EQ, Wang ZC, Sang YQ, Bi ZM, Ren CA, Zhou F, Liu GQ, Peng J, Hou M. High-dose dexamethasone vs prednisone for treatment of adult immune thrombocytopenia: a prospective multicenter randomized trial. Blood. 2016 Jan 21;127(3):296-302. Epub 2015 Oct 19. link to original article contains verified protocol PubMed
Dexamethasone & Eltrombopag
| back to top |
Regimen
| Study | Evidence |
| Gómez-Almaguer et al. 2014 | Pilot, <20 pts reported |
- Dexamethasone (Decadron) 40 mg/day PO on days 1 to 4
- Eltrombopag (Promacta) 50 mg PO once per day on days 5 to 33
One course
References
- Gómez-Almaguer D, Herrera-Rojas MA, Jaime-Pérez JC, Gómez-De León A, Cantú-Rodríguez OG, Gutiérrez-Aguirre CH, Tarín-Arzaga L, Hernández-Reyes J, Ruiz-Arguelles GJ. Eltrombopag and high-dose dexamethasone as frontline treatment of newly diagnosed immune thrombocytopenia in adults. Blood. 2014 Jun 19;123(25):3906-8. Epub 2014 May 6. link to original article contains verified protocol PubMed
Dexamethasone & Rituximab
| back to top |
Regimen ("R+3Dex")
| Study | Evidence |
| Imahiyerobo et al. 2013 | Retrospective |
- Dexamethasone (Decadron) 28 mg/m2/day (max dose of 40 mg) on days 1 to 4, repeated every 2 weeks for 3 cycles
- Rituximab (Rituxan) 375 mg/m2 IV once per week on weeks 1 to 4
References
- Abstract: Retrospective: Allison Imahiyerobo, Micha Thompson, Marina Izak Karaev, Waleed Ghanima, James B Bussel. Rituximab Combined With Three Cycles Of High Dose Dexamethasone Provides a Long Term Response Rate Similar To That Of Splenectomy In Patients With Immune Thrombocytopenia (ITP) Of Duration Less Than 2 Years. Blood Nov 2013,122(21)2310. link to abstract
Prednisone (Sterapred)
| back to top |
Regimen #1
| Study | Evidence | Comparator | Efficacy |
| Wei et al. 2015 | Phase III | Dexamethasone | Inferior CR rate |
- Prednisone (Sterapred) as follows:
- 1 mg/kg/day PO on days 1 to 28
- Afterwards, tapered over 4 to 6 weeks with a goal of maintenance dosing less than 15 mg/day or "complete termination"
- Taper schedule determined by treating physician
Regimen #2
| Study | Evidence | Comparator | Efficacy |
| Matschke et al. 2013 | Phase III | Dexamethasone | Seems not superior |
- Prednisone (Sterapred) as follows:
- 1 mg/kg/day PO on days 1 to 14
- Afterwards, tapered over 19 weeks with a goal of maintenance dosing less than 7.5 mg/day at the end of week 19
References
- Abstract: Johannes Matschke, Hannes Müller-Beißenhirtz, Ilona Vester, Bernd Hertenstein, Lewin Eisele, Hildegard Lax, Claudia Ose, Ulrich Dührsen. A Randomized Trial Of Daily Prednisone Versus Pulsed Dexamethasone In Treatment Naïve Patients With Idiopathic Thrombocytopenic Purpura. Blood Nov 2013,122(21)325. link to abstract
- Wei Y, Ji XB, Wang YW, Wang JX, Yang EQ, Wang ZC, Sang YQ, Bi ZM, Ren CA, Zhou F, Liu GQ, Peng J, Hou M. High-dose dexamethasone vs prednisone for treatment of adult immune thrombocytopenia: a prospective multicenter randomized trial. Blood. 2016 Jan 21;127(3):296-302. Epub 2015 Oct 19. link to original article contains verified protocol PubMed
Rho(D) immune globulin (RhoGAM)
| back to top |
Regimen
| Study | Evidence |
| Newman et al. 2001 | Randomized Phase II, <20 per arm |
Note: this medication is only effective in RhD-positive patients. The approved dose it 50 µg/kg but there is some data to support a higher dose of 75 µg/kg.
- Rho(D) immune globulin (RhoGAM) 50 µg/kg IV once
Supportive medications:
- Acetaminophen (Tylenol) 650 mg PO once prior to Rho(D) immune globulin (RhoGAM)
- Prednisone (Sterapred) 20 mg PO once prior to Rho(D) immune globulin (RhoGAM)
Can be repeated if required to increase platelet count
References
- Bussel JB, Graziano JN, Kimberly RP, Pahwa S, Aledort LM. Intravenous anti-D treatment of immune thrombocytopenic purpura: analysis of efficacy, toxicity, and mechanism of effect. Blood. 1991 May 1;77(9):1884-93. link to original article PubMed
- Newman GC, Novoa MV, Fodero EM, Lesser ML, Woloski BM, Bussel JB. A dose of 75 microg/kg/d of i.v. anti-D increases the platelet count more rapidly and for a longer period of time than 50 microg/kg/d in adults with immune thrombocytopenic purpura. Br J Haematol. 2001 Mar;112(4):1076-8. link to original article contains verified protocol PubMed
TT4
| back to top |
TT4: Triple Therapy (4?)
Regimen
| Study | Evidence |
| Choi et al. 2015 | Phase II |
The authors do not specify whether modified or non-modified cyclosporine was used in this protocol. Please contact them for clarifications.
- Dexamethasone (Decadron) 40 mg/day PO on days 1 to 4
- Cyclosporine 2.5 to 3 mg/kg/day on days 1 to 28
- Dose adjusted for target trough of 200 to 400 mcg/L
- Rituximab (Rituxan) 100 mg IV once per day on days 7, 14, 21, 28
References
- Choi PY, Roncolato F, Badoux X, Ramanathan S, Ho SJ, Chong BH. A novel triple therapy for ITP using high-dose dexamethasone, low-dose rituximab, and cyclosporine (TT4). Blood. 2015 Jul 23;126(4):500-3. Epub 2015 May 13. link to original article contains protocol link to PMC article PubMed
Relapsed/Refractory
Cyclosporine
| back to top |
Regimen
| Study | Evidence |
| Emilia et al. 2002 | Pilot, <20 pts |
The authors do not specify whether modified or non-modified cyclosporine was used in this protocol. Please contact them for clarifications.
- Cyclosporine as follows:
- 5 mg/kg/day PO split into twice daily dosing for 6 days, then
- 2.5 to 3 mg/kg/day with dose adjusted for target trough of 200 to 400 mcg/L
References
- Emilia G, Morselli M, Luppi M, Longo G, Marasca R, Gandini G, Ferrara L, D'Apollo N, Potenza L, Bertesi M, Torelli G. Long-term salvage therapy with cyclosporin A in refractory idiopathic thrombocytopenic purpura. Blood. 2002 Feb 15;99(4):1482-5. link to original article contains verified protocol PubMed
Danazol (Danocrine)
| back to top |
Regimen
| Study | Evidence |
| Ahn et al. 1983 | Pilot, >20 pts |
- Danazol (Danocrine) 200 mg PO two to four times per day
Given for at least 2 months
References
- Ahn YS, Harrington WJ, Simon SR, Mylvaganam R, Pall LM, So AG. Danazol for the treatment of idiopathic thrombocytopenic purpura. N Engl J Med. 1983 Jun 9;308(23):1396-9. link to original article contains verified protocol PubMed
Dexamethasone, high-dose
| back to top |
Regimen
| Study | Evidence |
| Andersen et al. 1994 | Pilot, <20 pts |
- Dexamethasone (Decadron) 40 mg PO once per day on days 1 to 4
28-day cycles for 6 cycles
References
- Andersen JC. Response of resistant idiopathic thrombocytopenic purpura to pulsed high-dose dexamethasone therapy. N Engl J Med. 1994 Jun 2;330(22):1560-4. link to original article contains verified protocol PubMed
Dexamethasone & Rituximab
| back to top |
Regimen ("R+3Dex")
| Study | Evidence |
| Imahiyerobo et al. 2013 | Retrospective |
- Dexamethasone (Decadron) 28 mg/m2/day (max dose of 40 mg) on days 1 to 4, repeated every 2 weeks for 3 cycles
- Rituximab (Rituxan) 375 mg/m2 IV once per week on weeks 1 to 4
References
- Abstract: Allison Imahiyerobo, Micha Thompson, Marina Izak Karaev, Waleed Ghanima, James B Bussel. Rituximab Combined With Three Cycles Of High Dose Dexamethasone Provides a Long Term Response Rate Similar To That Of Splenectomy In Patients With Immune Thrombocytopenia (ITP) Of Duration Less Than 2 Years. Blood Nov 2013,122(21)2310. link to abstract
Eltrombopag (Promacta)
| back to top |
Regimen #1
| Study | Evidence | Comparator | Efficacy |
| Grainger et al. 2015 (PETIT2) | Phase III | Placebo | Superior durable platelet response |
This regimen was intended for pediatric patients.
- Eltrombopag (Promacta) with starting dose as follows:
- Age 6 to 17, weighing at least 27kg, non-east Asian: 50 mg PO once per day
- Age 6 to 17, weighing at least 27kg, east Asian: 25 mg PO once per day
- Age 6 to 17, weighing less than 27kg, non-east Asian: 37.5 mg PO once per day
- Age 6 to 17, weighing less than 27kg, east Asian: 25 mg PO once per day
- Age 1 to 5, non-east Asian: 1.2 mg/kg/day oral suspension
- Age 1 to 5, east Asian: 0.8 mg/kg/day oral suspension
Dose adjusted to a maximum of 75 mg/day, with temporary discontinuation for platelet count greater than 400 x 109/L
Regimen #2
| Study | Evidence | Comparator | Efficacy |
| Bussel et al. 2009 | Phase III | Placebo | Superior plt count of greater than or equal to 50 x 109/L on day 43 |
- Eltrombopag (Promacta) 50 mg (starting dose) PO once per day
The dose could be increased from 50 mg to 75 mg after 3 weeks in patients whose platelet counts were less than 50 x 109/L. Treatment was discontinued in patients who attained a platelet count greater than 200 x 109/L
Regimen #3
| Study | Evidence | Comparator | Efficacy |
| Cheng et al. 2010 (RAISE) | Phase III | Placebo | Superior RR |
- Eltrombopag (Promacta) 50 mg PO once per day, with dose modifications:
Dose modifications:
- Increase to 75 mg PO once per day allowed after day 22 for patients with platelet counts lower than 50 x 109/L
- Decrease to 25 mg PO once per day required for platelets counts between 200 and 400 x 109/L
- Drug was held for platelet count greater than 400 x 109/L, until platelet count dropped below 150 x 109/L
6-month course
Regimen #4
| Study | Evidence | Comparator | Efficacy |
| Bussel et al. 2007 | Phase III | Placebo | Superior RR |
- Eltrombopag (Promacta) 50 mg PO once per day
Up to 6-week course
Regimen #5
| Study | Evidence |
| Saleh et al. 2012 (EXTEND) | Phase II |
- Eltrombopag (Promacta) 50 mg PO once per day, with adjustments:
Dose and schedule were individualized with the goal of achieving and maintaining platelets between 50 and 200 x 109/L.
References
- Bussel JB, Cheng G, Saleh MN, Psaila B, Kovaleva L, Meddeb B, Kloczko J, Hassani H, Mayer B, Stone NL, Arning M, Provan D, Jenkins JM. Eltrombopag for the treatment of chronic idiopathic thrombocytopenic purpura. N Engl J Med. 2007 Nov 29;357(22):2237-47. link to original article PubMed
- Bussel JB, Provan D, Shamsi T, Cheng G, Psaila B, Kovaleva L, Salama A, Jenkins JM, Roychowdhury D, Mayer B, Stone N, Arning M. Effect of eltrombopag on platelet counts and bleeding during treatment of chronic idiopathic thrombocytopenic purpura: a randomised, double-blind, placebo-controlled trial. Lancet. 2009 Feb 21;373(9664):641-8. link to original article contains verified protocol PubMed
- Cheng G, Saleh MN, Marcher C, Vasey S, Mayer B, Aivado M, Arning M, Stone NL, Bussel JB. Eltrombopag for management of chronic immune thrombocytopenia RAISE): a 6-month, randomised, phase 3 study. Lancet. 2011 Jan 29;377(9763):393-402. Epub 2010 Aug 23. Erratum in: Lancet. 2011 Jan 29;377(9763):382. link to original article contains verified protocol PubMed
- Saleh MN, Bussel JB, Cheng G, Meyer O, Bailey CK, Arning M, Brainsky A; EXTEND Study Group. Safety and efficacy of eltrombopag for treatment of chronic immune thrombocytopenia: results of the long-term, open-label EXTEND study. Blood. 2013 Jan 17;121(3):537-45. Epub 2012 Nov 20. link to original article contains verified protocol PubMed
- Grainger JD, Locatelli F, Chotsampancharoen T, Donyush E, Pongtanakul B, Komvilaisak P, Sosothikul D, Drelichman G, Sirachainan N, Holzhauer S, Lebedev V, Lemons R, Pospisilova D, Ramenghi U, Bussel JB, Bakshi KK, Iyengar M, Chan GW, Chagin KD, Theodore D, Marcello LM, Bailey CK. Eltrombopag for children with chronic immune thrombocytopenia (PETIT2): a randomised, multicentre, placebo-controlled trial. Lancet. 2015 Jul 28. [Epub ahead of print] link to original article contains verified protocol PubMed
- Yang R, Li J, Jin J, Huang M, Yu Z, Xu X, Zhang X, Hou M. Multicentre, randomised phase III study of the efficacy and safety of eltrombopag in Chinese patients with chronic immune thrombocytopenia. Br J Haematol. 2017 Jan;176(1):101-110. link to original article PubMed
Mycophenolate mofetil (CellCept)
| back to top |
Regimen
| Study | Evidence |
| Taylor et al. 2015 | Retrospective |
- Mycophenolate mofetil (CellCept) 1 gm per day
References
- Taylor A, Neave L, Solanki S, Westwood JP, Terrinonive I, McGuckin S, Kothari J, Cooper N, Stasi R, Scully M. Mycophenolate mofetil therapy for severe immune thrombocytopenia. Br J Haematol. 2015 Nov;171(4):625-30. Epub 2015 Aug 6. link to original article PubMed
Placebo
| back to top |
Regimen
| Study | Evidence | Comparator | Efficacy |
| Kuter et al. 2008 | Phase III | Romiplostim | Inferior durable platelet response |
| Bussel et al. 2007 | Phase III | Eltrombopag | Inferior RR |
| Cheng et al. 2010 (RAISE) | Phase III | Eltrombopag | Inferior RR |
| Ghanima et al. 2015 (RITP) | Phase III | Rituximab | Seems not superior |
| Grainger et al. 2015 (PETIT2) | Phase III | Eltrombopag | Inferior durable platelet response |
| Tarantino et al. 2016 | Phase III | Romiplostim | Inferior durable platelet response |
No active treatment; used as a comparator arm and here for reference purposes only.
References
- Kuter DJ, Bussel JB, Lyons RM, Pullarkat V, Gernsheimer TB, Senecal FM, Aledort LM, George JN, Kessler CM, Sanz MA, Liebman HA, Slovick FT, de Wolf JT, Bourgeois E, Guthrie TH Jr, Newland A, Wasser JS, Hamburg SI, Grande C, Lefrère F, Lichtin AE, Tarantino MD, Terebelo HR, Viallard JF, Cuevas FJ, Go RS, Henry DH, Redner RL, Rice L, Schipperus MR, Guo DM, Nichol JL. Efficacy of romiplostim in patients with chronic immune thrombocytopenic purpura: a double-blind randomised controlled trial. Lancet. 2008 Feb 2;371(9610):395-403. link to original article PubMed
- Bussel JB, Provan D, Shamsi T, Cheng G, Psaila B, Kovaleva L, Salama A, Jenkins JM, Roychowdhury D, Mayer B, Stone N, Arning M. Effect of eltrombopag on platelet counts and bleeding during treatment of chronic idiopathic thrombocytopenic purpura: a randomised, double-blind, placebo-controlled trial. Lancet. 2009 Feb 21;373(9664):641-8. link to original article contains verified protocol PubMed
- Cheng G, Saleh MN, Marcher C, Vasey S, Mayer B, Aivado M, Arning M, Stone NL, Bussel JB. Eltrombopag for management of chronic immune thrombocytopenia RAISE): a 6-month, randomised, phase 3 study. Lancet. 2011 Jan 29;377(9763):393-402. Epub 2010 Aug 23. Erratum in: Lancet. 2011 Jan 29;377(9763):382. link to original article contains verified protocol PubMed
- Ghanima W, Khelif A, Waage A, Michel M, Tjønnfjord GE, Romdhan NB, Kahrs J, Darne B, Holme PA; on behalf of the RITP study group. Rituximab as second-line treatment for adult immune thrombocytopenia (the RITP trial): a multicentre, randomised, double-blind, placebo-controlled trial. Lancet. 2015 Apr 25;385(9978):1653-61. Epub 2015 Feb 4. link to original article contains protocol PubMed
- Grainger JD, Locatelli F, Chotsampancharoen T, Donyush E, Pongtanakul B, Komvilaisak P, Sosothikul D, Drelichman G, Sirachainan N, Holzhauer S, Lebedev V, Lemons R, Pospisilova D, Ramenghi U, Bussel JB, Bakshi KK, Iyengar M, Chan GW, Chagin KD, Theodore D, Marcello LM, Bailey CK. Eltrombopag for children with chronic immune thrombocytopenia (PETIT2): a randomised, multicentre, placebo-controlled trial. Lancet. 2015 Jul 28. [Epub ahead of print] link to original article contains verified protocol PubMed
- Tarantino MD, Bussel JB, Blanchette VS, Despotovic J, Bennett C, Raj A, Williams B, Beam D, Morales J, Rose MJ, Carpenter N, Nie K, Eisen M. Romiplostim in children with immune thrombocytopenia: a phase 3, randomised, double-blind, placebo-controlled study. Lancet. 2016 Apr 18. [Epub ahead of print] link to original article contains verified protocol PubMed
- Yang R, Li J, Jin J, Huang M, Yu Z, Xu X, Zhang X, Hou M. Multicentre, randomised phase III study of the efficacy and safety of eltrombopag in Chinese patients with chronic immune thrombocytopenia. Br J Haematol. 2017 Jan;176(1):101-110. link to original article PubMed
Rituximab monotherapy
| back to top |
Regimen
| Study | Evidence | Comparator | Efficacy |
| Godeau et al. 2008 | Phase II | ||
| Ghanima et al. 2015 (RITP) | Phase III | Placebo | Seems not superior |
Patients in Godeau et al. 2008 had "ITP lasting 6 or more months before inclusion; at least 1 previous treatment for ITP; and platelet count less than 30 × 109/L at inclusion" and were candidates for splenectomy."
- Rituximab (Rituxan) 375 mg/m2 IV once per week
Supportive medications (per Godeau et al. 2008):
- Patients received Streptococcus pneumoniae and Haemophilus influenzae vaccination at least 2 weeks before the first dose of Rituximab (Rituxan)
- Acetaminophen (Tylenol) 1 g prior to Rituximab (Rituxan)
- Methylprednisolone (Solumedrol) 60 mg IV prior to Rituximab (Rituxan)
4-week course
References
- Godeau B, Porcher R, Fain O, Lefrère F, Fenaux P, Cheze S, Vekhoff A, Chauveheid MP, Stirnemann J, Galicier L, Bourgeois E, Haiat S, Varet B, Leporrier M, Papo T, Khellaf M, Michel M, Bierling P. Rituximab efficacy and safety in adult splenectomy candidates with chronic immune thrombocytopenic purpura: results of a prospective multicenter phase 2 study. Blood. 2008 Aug 15;112(4):999-1004. link to original article contains verified protocol PubMed
- Prospective cohort: Patel VL, Mahévas M, Lee SY, Stasi R, Cunningham-Rundles S, Godeau B, Kanter J, Neufeld E, Taube T, Ramenghi U, Shenoy S, Ward MJ, Mihatov N, Patel VL, Bierling P, Lesser M, Cooper N, Bussel JB. Outcomes 5 years after response to rituximab therapy in children and adults with immune thrombocytopenia. Blood. 2012 Jun 21;119(25):5989-95. link to original article contains verified protocol link to PMC article PubMed
- Ghanima W, Khelif A, Waage A, Michel M, Tjønnfjord GE, Romdhan NB, Kahrs J, Darne B, Holme PA; on behalf of the RITP study group. Rituximab as second-line treatment for adult immune thrombocytopenia (the RITP trial): a multicentre, randomised, double-blind, placebo-controlled trial. Lancet. 2015 Apr 25;385(9978):1653-61. Epub 2015 Feb 4.link to original article contains protocol PubMed
Romiplostim (Nplate)
| back to top |
Regimen
| Study | Evidence | Comparator | Efficacy |
| Kuter et al. 2008 | Phase III | Placebo | Superior durable platelet response |
| Tarantino et al. 2016 | Phase III | Placebo | Superior durable platelet response |
Patients in Kuter et al. 2008 were adults; some had undergone splenectomy. Patients in Tarantino et al. 2016 were less than 18 years old at time of study entry.
- Romiplostim (Nplate) 1 μg/kg SC once per week, with subsequent dose titration; see papers for details
References
- Kuter DJ, Bussel JB, Lyons RM, Pullarkat V, Gernsheimer TB, Senecal FM, Aledort LM, George JN, Kessler CM, Sanz MA, Liebman HA, Slovick FT, de Wolf JT, Bourgeois E, Guthrie TH Jr, Newland A, Wasser JS, Hamburg SI, Grande C, Lefrère F, Lichtin AE, Tarantino MD, Terebelo HR, Viallard JF, Cuevas FJ, Go RS, Henry DH, Redner RL, Rice L, Schipperus MR, Guo DM, Nichol JL. Efficacy of romiplostim in patients with chronic immune thrombocytopenic purpura: a double-blind randomised controlled trial. Lancet. 2008 Feb 2;371(9610):395-403. link to original article contains verified protocol PubMed
- Tarantino MD, Bussel JB, Blanchette VS, Despotovic J, Bennett C, Raj A, Williams B, Beam D, Morales J, Rose MJ, Carpenter N, Nie K, Eisen M. Romiplostim in children with immune thrombocytopenia: a phase 3, randomised, double-blind, placebo-controlled study. Lancet. 2016 Apr 18. [Epub ahead of print] link to original article contains verified protocol PubMed